# Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

> **NCT01407406** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BIIB023 - low dose IV Dose
- **DRUG:** BIIB023 - high dose IV Dose

## Key facts

- **NCT ID:** NCT01407406
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01407406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01407406, "Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01407406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*